menu
    • menu
    [{"orgOrder":0,"company":"CytoImmune Therapeutics","sponsor":"Cytovia Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Acquisition","leadProduct":"CYT-101","moa":"Dual EGFR","graph1":"Oncology","graph2":"IND Enabling","graph3":"CytoImmune Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intracranial Injection","sponsorNew":"CytoImmune Therapeutics \/ Cytovia Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"CytoImmune Therapeutics \/ Cytovia Therapeutics"},{"orgOrder":0,"company":"CytoImmune Therapeutics","sponsor":"City of Hope","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Licensing Agreement","leadProduct":"CYTO NK-203","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"CytoImmune Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"CytoImmune Therapeutics \/ City of Hope","highestDevelopmentStatusID":"5","companyTruncated":"CytoImmune Therapeutics \/ City of Hope"},{"orgOrder":0,"company":"CytoImmune Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"CYTO NK-201","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"CytoImmune Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"CytoImmune Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"CytoImmune Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"CytoImmune Therapeutics","sponsor":"City of Hope","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"CytoImmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"CytoImmune Therapeutics \/ City of Hope","highestDevelopmentStatusID":"6","companyTruncated":"CytoImmune Therapeutics \/ City of Hope"}]

    Find Clinical Drug Pipeline Developments & Deals by CytoImmune Therapeutics

    Menu

    CytoImmune Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            CytoImmune Therapeutics

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            CytoImmune Therapeutics

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CYTO-102,Atezolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : City of Hope

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            CytoImmune Therapeutics and City of Hope Announce First Patient Dosed in a Phase 1 Trial Evaluating a Novel Of...

                            Details : CYTO-102 to be an off-the-shelf cell therapy that can directly kill cancer cells, broadly stimulate the body’s own endogenous immune system, and enhance tumor killing through generation of a highly effective immune response ultimately leading to improv...

                            Brand Name : CYTO-102

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            July 28, 2022

                            Lead Product(s) : CYTO-102,Atezolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : City of Hope

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            CytoImmune Therapeutics

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            CytoImmune Therapeutics

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CYTO NK-201

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            CytoImmune to Present New Preclinical Data Highlighting Potential of Novel TRACK-NK Cell Therapies as Treatmen...

                            Details : CYTO NK-201, an engineered, allogeneic, tumor-reactive natural killer (TRACK-NK) and FLT3, directly attack cancer cells and broadly stimulate both innate and adaptive arms of immune system through potent IL-15 secretion enabling potential for potent and ...

                            Brand Name : CYTO NK-201

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            March 08, 2022

                            Lead Product(s) : CYTO NK-201

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            CytoImmune Therapeutics

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            CytoImmune Therapeutics

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CYTO NK-203

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : City of Hope

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            City of Hope Enters Licensing Agreements with CytoImmune Therapeutics to Develop Portfolio of Chimeric Antigen...

                            Details : The agreements include licenses to several patent applications related to methods to generate large numbers of fully functional natural killer (NK) cells derived from umbilical cord blood and compositions of chimeric receptors (CAR) for targeting NK cell...

                            Brand Name : CYTO NK-203

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            April 08, 2021

                            Lead Product(s) : CYTO NK-203

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : City of Hope

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            CytoImmune Therapeutics

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            CytoImmune Therapeutics

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CYT-101

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Cytovia Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Cytovia Therapeutics Acquires Worldwide Rights to CytoImmune Therapeutics’ First-In-Class EGFR Dual-targetin...

                            Details : Cytovia will conduct and finance all future development and will apply the EGFR Dual-targeting CAR to its iPSC CAR NK technology. CytoImmune will receive an upfront equity grant in Cytovia, future development milestones, and royalties.

                            Brand Name : CYT-101

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            August 03, 2020

                            Lead Product(s) : CYT-101

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Cytovia Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth